Indivior Pharmaceuticals, Inc 6-K, filed Apr 8, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-04-08
For: 2024-04-08
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on April 8, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: April 08, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: April 08,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
Indivior
to Announce Q1 2024 Results and Host Webcast on April
25th
Slough, UK, and Richmond, VA, April 8,
2024 - Indivior PLC (LSE/NASDAQ: INDV) today announced
that it will release its Q1 2024 results on April
25th at
7:00 a.m. London time (2:00 a.m. U.S. Eastern).
The results will be
available via the London Stock Exchange's Regulatory News Service
(RNS) and on the "Investors" section of the company's website
at www.indivior.com.
Mark Crossley, Chief Executive Officer, and other members of
Indivior's leadership team will host a presentation via live
webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on April
25th.
Access to the Live Webcast Presentation:
The webcast event and materials can be accessed on the "Investors"
section of the company's website at www.indivior.com before
the event begins.
The webcast link: https://edge.media-server.com/mmc/p/hktzzit4
Participants may access the presentation telephonically by
registering with the following link:
https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519
(Registrants will have an
option to be called back directly immediately prior to the call or
be provided a call-in # with a unique pin code following their
registration)
A replay of the presentation will be available
at www.indivior.com.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in
Richmond, VA, Indivior employs more than 1,000 individuals globally
and its portfolio of products is available in 37 countries
worldwide. Visit www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/
company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###